by rss feed | May 25, 2025 | CRISPR therapy, Editas, News Feeds, Verve Therapeutics, weekly reads
There has been a sizable downturn for the CRISPR therapy biotech arena. Firms like Editas, Verve, Intellia, and even CRISPR Therapeutics, which has garnered an FDA approval, have had struggles recently. It feels like a disconnect here in a way because overall gene...
by rss feed | Oct 3, 2021 | Editas, News Feeds, the Niche
The news of the week relates to an interim clinical trial report from gene-editing firm Editas on its CRISPR trial for a form of vision loss. On to that in a minute. What have you been reading the past week? Below, I include our weekly list of recommended reads....
